{"context":{"query":">>chembl_molecule>>clinical_trials","source_dataset":"chembl_molecule","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":66,"mapped":1},"pagination":{"has_next":false},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"CHEMBL1738797","source":"CHEMBL1738797|ALECTINIB","targets":["NCT05525338|Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels|RECRUITING|PHASE4|INTERVENTIONAL","NCT02075840|A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants|COMPLETED|PHASE3|INTERVENTIONAL","NCT02604342|Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib|COMPLETED|PHASE3|INTERVENTIONAL","NCT02838420|A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03178552|A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)|ACTIVE_NOT_RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT03194893|A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03596866|A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT03768063|A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05170204|A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05722886|DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol|RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT05770037|DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers|RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT06624059|A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT06765109|Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC|RECRUITING|PHASE3|INTERVENTIONAL","NCT01801111|A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT01871805|A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT02091141|My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors|COMPLETED|PHASE2|INTERVENTIONAL","NCT02314481|Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT02521051|Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer|TERMINATED|PHASE1/PHASE2|INTERVENTIONAL","NCT02925234|The Drug Rediscovery Protocol (DRUP Trial)|RECRUITING|PHASE2|INTERVENTIONAL","NCT03131206|A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer|TERMINATED|PHASE1/PHASE2|INTERVENTIONAL","NCT03155009|A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT03158389|NCT Neuro Master Match - N²M² (NOA-20)|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT03202940|A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC|ACTIVE_NOT_RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT03445000|ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer|TERMINATED|PHASE2|INTERVENTIONAL","NCT03498521|A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site|COMPLETED|PHASE2|INTERVENTIONAL","NCT03737994|Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT03779191|Alectinib in Combination With Bevacizumab in ALK Positive NSCLC|COMPLETED|PHASE2|INTERVENTIONAL","NCT03944772|Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT04116541|A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.|RECRUITING|PHASE2|INTERVENTIONAL","NCT04302025|A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)|RECRUITING|PHASE2|INTERVENTIONAL","NCT04322890|Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation|RECRUITING|PHASE2|INTERVENTIONAL","NCT04341181|ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling|RECRUITING|PHASE2|INTERVENTIONAL","NCT04423185|PLATFORM Study of Precision Medicine for Rare Tumors|RECRUITING|PHASE2|INTERVENTIONAL","NCT04551521|CRAFT: The NCT-PMO-1602 Phase II Trial|COMPLETED|PHASE2|INTERVENTIONAL","NCT04589845|Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study|RECRUITING|PHASE2|INTERVENTIONAL","NCT04591431|The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy|UNKNOWN|PHASE2|INTERVENTIONAL","NCT04632992|A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response|COMPLETED|PHASE2|INTERVENTIONAL","NCT04644315|A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors|TERMINATED|PHASE2|INTERVENTIONAL","NCT04774718|A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors|RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT05015010|Alectinib in Neo-adjuvant Treatment of Stage III NSCLC|ACTIVE_NOT_RECRUITING|PHASE2|INTERVENTIONAL","NCT05081674|Brazilian Lung Immunotherapy Study|COMPLETED|PHASE2|INTERVENTIONAL","NCT05159245|The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs|RECRUITING|PHASE2|INTERVENTIONAL","NCT05713006|Alectinib Pharmacokinetic in Patients With NSCLC|RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT05725200|Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer|RECRUITING|PHASE2|INTERVENTIONAL","NCT05987644|Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements|RECRUITING|PHASE1/PHASE2|INTERVENTIONAL","NCT06692491|Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS|NOT_YET_RECRUITING|PHASE2|INTERVENTIONAL","NCT01940510|A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802|COMPLETED|PHASE1|INTERVENTIONAL","NCT01981005|A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802|COMPLETED|PHASE1|INTERVENTIONAL","NCT01984229|A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers|COMPLETED|PHASE1|INTERVENTIONAL","NCT02013219|A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)|COMPLETED|PHASE1|INTERVENTIONAL","NCT02023125|A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.|COMPLETED|PHASE1|INTERVENTIONAL","NCT02621047|Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib|COMPLETED|PHASE1|INTERVENTIONAL","NCT05238831|SMMART Adaptive Clinical Treatment (ACT) Trial|WITHDRAWN|EARLY_PHASE1|INTERVENTIONAL","NCT07001384|A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)|RECRUITING|PHASE1|INTERVENTIONAL","NCT02271139|Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy|NO_LONGER_AVAILABLE|nan|EXPANDED_ACCESS","NCT03271554|Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea|COMPLETED|nan|OBSERVATIONAL","NCT03546894|A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors|COMPLETED|nan|OBSERVATIONAL","NCT04351334|Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns|COMPLETED|nan|OBSERVATIONAL","NCT04647110|Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.|COMPLETED|nan|OBSERVATIONAL","NCT04708639|Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients|UNKNOWN|nan|OBSERVATIONAL","NCT04764188|An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib|ACTIVE_NOT_RECRUITING|nan|OBSERVATIONAL","NCT05525858|KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II|RECRUITING|nan|OBSERVATIONAL","NCT05834348|A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.|COMPLETED|nan|OBSERVATIONAL","NCT06532149|ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer|RECRUITING|nan|OBSERVATIONAL","NCT06709274|Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC|NOT_YET_RECRUITING|nan|INTERVENTIONAL","NCT06862869|Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy|RECRUITING|nan|OBSERVATIONAL"]}]}